A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
Status:
Not yet recruiting
Trial end date:
2023-11-27
Target enrollment:
Participant gender:
Summary
The aim of this study is to measure the concentration levels of mezigdomide in the blood of
participants with mild, moderate, and severe hepatic impairment, and in matched healthy
control participants with normal hepatic function.